trending Market Intelligence /marketintelligence/en/news-insights/trending/C_6YFaOsGgMtZEBwBHoWqw2 content esgSubNav
In This List

Monopar Therapeutics files for Nasdaq IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Monopar Therapeutics files for Nasdaq IPO

Monopar Therapeutics LLC filed a prospectus with the U.S. Securities Exchange Commission for an IPO of its common shares to raise about $40.3 million.

The Illinois-based company has applied to list its shares on the Nasdaq Capital Market under the symbol MNPR.

Monopar Therapeutics, founded in 2014, plans to use the proceeds from the IPO to advance Validive, a medicine being developed to treat a complication arising from chemotherapy or radiotherapy in patients receiving treatment for oropharyngeal cancer.

JonesTrading Institutional Services LLC is the underwriter for the IPO.